Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression
Histone Arg methylation and Lys acetylation have been found to cooperatively regulate the expression of p53-target genes. Peptidylarginine deiminase 4 (PAD4) is an enzyme that citrullinates histone arginine and monomethyl-arginine residues thereby regulating histone Arg methylation. We have recently found that PAD4 serves as a p53 corepressor to regulate histone Arg methylation at the p53-target gene p21/WAF1/CIP1 promoter. However, it has not been tested whether histone Arg citrullination coordinates with other histone modifications to repress transcription. Here, we show that histone deacetylase (HDAC2) and PAD4 interact with p53 through distinct domains and simultaneously associate with the p21 promoter to regulate gene expression. After DNA damage, PAD4 and HDAC2 dissociate from several p53-target gene promoters (for example, p21, GADD45, and PUMA) with a concomitant increase in histone Lys acetylation and Arg methylation at these promoters. Furthermore, PAD4 promoter association and histone Arg modifications are regulated by p53 and HDAC activity. In contrast, HDAC2 promoter association and histone Lys acetylation are affected by p53 and PAD4 activity at minor degrees. Importantly, PAD4 inhibitor Cl-amidine and HDAC inhibitor suberoylanilide hydroxamic acid show additive effects in inducing p21, GADD45, and PUMA expression and inhibiting cancer cell growth in a p53-dependent manner. Our results unveil an important crosstalk between histone deacetylation and citrullination, suggesting that a combination of PAD4 and HDAC2 inhibitors as a potential strategy for cancer treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Oncogene - 29(2010), 21 vom: 27. Mai, Seite 3153-62 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, P [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.07.2010 Date Revised 20.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/onc.2010.51 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM195426819 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM195426819 | ||
| 003 | DE-627 | ||
| 005 | 20231223202738.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/onc.2010.51 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0651.xml |
| 035 | |a (DE-627)NLM195426819 | ||
| 035 | |a (NLM)20190809 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.07.2010 | ||
| 500 | |a Date Revised 20.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Histone Arg methylation and Lys acetylation have been found to cooperatively regulate the expression of p53-target genes. Peptidylarginine deiminase 4 (PAD4) is an enzyme that citrullinates histone arginine and monomethyl-arginine residues thereby regulating histone Arg methylation. We have recently found that PAD4 serves as a p53 corepressor to regulate histone Arg methylation at the p53-target gene p21/WAF1/CIP1 promoter. However, it has not been tested whether histone Arg citrullination coordinates with other histone modifications to repress transcription. Here, we show that histone deacetylase (HDAC2) and PAD4 interact with p53 through distinct domains and simultaneously associate with the p21 promoter to regulate gene expression. After DNA damage, PAD4 and HDAC2 dissociate from several p53-target gene promoters (for example, p21, GADD45, and PUMA) with a concomitant increase in histone Lys acetylation and Arg methylation at these promoters. Furthermore, PAD4 promoter association and histone Arg modifications are regulated by p53 and HDAC activity. In contrast, HDAC2 promoter association and histone Lys acetylation are affected by p53 and PAD4 activity at minor degrees. Importantly, PAD4 inhibitor Cl-amidine and HDAC inhibitor suberoylanilide hydroxamic acid show additive effects in inducing p21, GADD45, and PUMA expression and inhibiting cancer cell growth in a p53-dependent manner. Our results unveil an important crosstalk between histone deacetylation and citrullination, suggesting that a combination of PAD4 and HDAC2 inhibitors as a potential strategy for cancer treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Histones |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
| 650 | 7 | |a Citrulline |2 NLM | |
| 650 | 7 | |a 29VT07BGDA |2 NLM | |
| 650 | 7 | |a Arginine |2 NLM | |
| 650 | 7 | |a 94ZLA3W45F |2 NLM | |
| 650 | 7 | |a Hydrolases |2 NLM | |
| 650 | 7 | |a EC 3.- |2 NLM | |
| 650 | 7 | |a HDAC2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.5.1.98 |2 NLM | |
| 650 | 7 | |a Histone Deacetylase 2 |2 NLM | |
| 650 | 7 | |a EC 3.5.1.98 |2 NLM | |
| 650 | 7 | |a PADI4 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.5.3.15 |2 NLM | |
| 650 | 7 | |a Protein-Arginine Deiminase Type 4 |2 NLM | |
| 650 | 7 | |a EC 3.5.3.15 |2 NLM | |
| 650 | 7 | |a Protein-Arginine Deiminases |2 NLM | |
| 650 | 7 | |a EC 3.5.3.15 |2 NLM | |
| 650 | 7 | |a Lysine |2 NLM | |
| 650 | 7 | |a K3Z4F929H6 |2 NLM | |
| 700 | 1 | |a Wang, D |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, H |e verfasserin |4 aut | |
| 700 | 1 | |a Doret, P |e verfasserin |4 aut | |
| 700 | 1 | |a Hao, G |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Q |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, H |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, X |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, G |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Y |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncogene |d 1990 |g 29(2010), 21 vom: 27. Mai, Seite 3153-62 |w (DE-627)NLM012595683 |x 1476-5594 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2010 |g number:21 |g day:27 |g month:05 |g pages:3153-62 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/onc.2010.51 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2010 |e 21 |b 27 |c 05 |h 3153-62 | ||